» Articles » PMID: 33572190

Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year After Emerging

Overview
Journal Pathogens
Date 2021 Feb 12
PMID 33572190
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

In December 2019, the first cases of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were identified in the city of Wuhan, China. Since then, it has spread worldwide with new mutations being reported. The aim of the present study was to monitor the changes in genetic diversity and track non-synonymous substitutions () that could be implicated in the fitness of SARS-CoV-2 and its spread in different regions between December 2019 and November 2020. We analyzed 2213 complete genomes from six geographical regions worldwide, which were downloaded from GenBank and GISAID databases. Although SARS-CoV-2 presented low genetic diversity, there has been an increase over time, with the presence of several hotspot mutations throughout its genome. We identified seven frequent mutations that resulted in substitutions. Two of them, C14408T>P323L and A23403G>D614G, located in the nsp12 and Spike protein, respectively, emerged early in the pandemic and showed a considerable increase in frequency over time. Two other mutations, A1163T>I120F in nsp2 and G22992A>S477N in the Spike protein, emerged recently and have spread in Oceania and Europe. There were associations of P323L, D614G, R203K and G204R substitutions with disease severity. Continuous molecular surveillance of SARS-CoV-2 will be necessary to detect and describe the transmission dynamics of new variants of the virus with clinical relevance. This information is important to improve programs to control the virus.

Citing Articles

Virus-specific Dicer-substrate siRNA swarms inhibit SARS-CoV-2 infection in TMPRSS2-expressing Vero E6 cells.

Jiang M, Laine L, Kolehmainen P, Kakkola L, Avelin V, Vaisanen E Front Microbiol. 2024; 15:1432349.

PMID: 39611095 PMC: 11602746. DOI: 10.3389/fmicb.2024.1432349.


Complete genome sequencing of SARS-CoV-2 strains that were circulating in Uzbekistan over the course of four pandemic waves.

Esonova G, Abdurakhimov A, Ibragimova S, Kurmaeva D, Gulomov J, Mirazimov D PLoS One. 2024; 19(11):e0298940.

PMID: 39561193 PMC: 11575833. DOI: 10.1371/journal.pone.0298940.


Empowering public health: building advanced molecular surveillance in resource-limited settings through collaboration and capacity-building.

Koudokpon H, Legba B, Sintondji K, Kissira I, Kounou A, Guindo I Front Health Serv. 2024; 4:1289394.

PMID: 38957804 PMC: 11217560. DOI: 10.3389/frhs.2024.1289394.


Epidemiological Characterization and Genetic Variation of the SARS-CoV-2 Delta Variant in Palestine.

Ereqat S, Alikhan N, Al-Jawabreh A, Matthews M, Al-Jawabreh A, de Oliveira Martins L Pathogens. 2024; 13(6).

PMID: 38921818 PMC: 11206313. DOI: 10.3390/pathogens13060521.


Enteric coronavirus nsp2 is a virulence determinant that recruits NBR1 for autophagic targeting of TBK1 to diminish the innate immune response.

Jiao Y, Zhao P, Xu L, Yu J, Cai H, Zhang C Autophagy. 2024; 20(8):1762-1779.

PMID: 38597182 PMC: 11262224. DOI: 10.1080/15548627.2024.2340420.


References
1.
Laiton-Donato K, Villabona-Arenas C, Usme-Ciro J, Franco-Munoz C, Alvarez-Diaz D, Villabona-Arenas L . Genomic Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2, Colombia. Emerg Infect Dis. 2020; 26(12):2854-2862. PMC: 7706936. DOI: 10.3201/eid2612.202969. View

2.
Volz E, Hill V, McCrone J, Price A, Jorgensen D, OToole A . Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell. 2020; 184(1):64-75.e11. PMC: 7674007. DOI: 10.1016/j.cell.2020.11.020. View

3.
Holmes E, Dudas G, Rambaut A, Andersen K . The evolution of Ebola virus: Insights from the 2013-2016 epidemic. Nature. 2016; 538(7624):193-200. PMC: 5580494. DOI: 10.1038/nature19790. View

4.
Korber B, Fischer W, Gnanakaran S, Yoon H, Theiler J, Abfalterer W . Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020; 182(4):812-827.e19. PMC: 7332439. DOI: 10.1016/j.cell.2020.06.043. View

5.
Greaney A, Loes A, Crawford K, Starr T, Malone K, Chu H . Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021; 29(3):463-476.e6. PMC: 7869748. DOI: 10.1016/j.chom.2021.02.003. View